Skip to main content

Advertisement

Fig. 3 | Journal of Experimental & Clinical Cancer Research

Fig. 3

From: The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma

Fig. 3

AZD9291 suppressed the migration and invasion of GBM cell. a and c Cell migratory ability of the control group and the AZD9291-treated groups were detected by wound healing assay in U87 and U251 cells. b and d Quantitative analysis of migratory cell numbers. e and g Effects of AZD9291 on invasion ability of U87 and U251 cells as examined by transwell assay. f and h Quantitative analysis of invading cell numbers. The numbers of migratory and invading cells were normalized to that of the control group. The values were presented as the means ± SEM, *P < 0.05, versus the control

Back to article page